FDA Approves Eli Lilly's Weight-Loss Pill Foundayo

0:00FDA just greenlit Eli Lilly's new weight loss pill called Foundale, marking the second oral GLP-1 drug, okayed in the U.S. after Novo Nordisk's Wigovii. Back in December 2025, it's a once daily pill aimed at adults battling obesity or those overweight with related health issues, meant to shed extra pounds when paired with A, calorie cut diet and more exercise. Disapproval came lightning fast, just 50 days after filing, showing how streamline reviews can move things along. In trials, folks on the top dose who stuck with it dropped an average of 27.3 pounds, way more than the 2.2 pounds from, placebo. Reactions from the FDA highlight their push for quick yet solid checks with industry partners. For dosing, it starts at 0.8 milligrams, ramps to 2.5 after 30 days, then 5.5 and higher up to 17. 1.2 based on how you handle it, uninsured patients face $149 a month, common side effects

1:03hit the gut hard, hard nausea, constipation, diarrhea, vomiting, plus headaches, fatigue and even hair loss. There's a warning on potential thyroid tumors and past studies link GLP-1 drugs to risks like stomach paralysis, pancreatitis, bowel blocks, and even vision loss. As these pills hit shelves, keep an eye on real-world data and doc chats to weigh benefits against those edges, weight management evolving, but smart, play stay key. That wraps Canada News today, brought to you with AI. I'm Cory with the story.